Pfizer Nears $7.3 Billion Deal for Metsera Acquisition
Pfizer, one of the world’s largest pharmaceutical companies, is moving closer to a major acquisition valued at around $7.3 billion. The company is reportedly finalizing a deal to buy Metsera, a biotech firm focused on weight-loss drugs and metabolic treatments. This move highlights Pfizer’s ambition to expand into one of the fastest-growing markets in healthcare, obesity, and metabolic therapies.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
